Hemostatic factors and the metabolic syndrome

Current Vascular Pharmacology

Volumn 11, Issue 6, 2013, Pages 880-905

  Kostapanos, Michael S ^a,b   Florentin, Matilda ^b   Elisaf, Moses S ^b   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Coagulation; Endothelium; Fibrinolysis; Hemostasis; Metabolic syndrome; Platelet; Viscosity

Indexed keywords

ANGIOTENSIN II; BLOOD CLOTTING FACTOR 7; ENDOTHELIN 1; FIBRINOGEN; THROMBOPLASTIN; THROMBOXANE A2; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; BLOOD FLOW; BLOOD VISCOSITY; DIET; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; VASODILATATION; WEIGHT REDUCTION;

ANIMALS; BLOOD COAGULATION; DIET, MEDITERRANEAN; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HEMOSTASIS; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84893515280     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660171     Document Type: Review

References (427)

1. Hauner H. Insulin resistance and the metabolic syndrome-a challenge of the new millennium. Eur J Clin Nutr 2002; 56: S25-9.
2. Desroches S, Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome. Appl Physiol Nutr Metab 2007; 32: 23-32.
3. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010; 2: 180-93.
4. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 2004; 147: 106-12.
5. Panagiotakos DB, Pitsavos C, Skoumas Y, Stefanadis C. The association between food patterns and the metabolic syndrome using principal components analysis: The ATTICA Study. J Am Diet Assoc 2007; 107: 979-87.
6. Tzima N, Pitsavos C, Panagiotakos DB, et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. Nutr Metab (Lond) 2009; 6: 30.
7. Malik S, Budoff MJ, Katz R, et al. Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis. Diabetes Care 2011; 34: 2285-90.
8. Kikano GE, Brown MT. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. Mayo Clin Proc 2007; 82: 583-93.
9. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56: 1113-32.
10. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-19.
11. Ballantyne CM, Hoogeveen RC, McNeill AM, et al. Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study. Int J Obes (Lond) 2008; 32: S21-4.
12. Milionis HJ, Kostapanos MS, Liberopoulos EN, et al. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Int J Clin Pract 2007; 61: 545-51.
13. Li W, Ma D, Liu M, et al. Association between metabolic syndrome and risk of stroke: a meta-analysis of cohort studies. Cerebrovasc Dis 2008; 25: 539-47.
14. Brodov Y, Behar S, Boyko V, Chouraqui P. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study). Am J Cardiol 2010; 106: 1717-20.
15. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005; 36: 1372-76.
16. Steffen LM, Cushman M, Peacock JM, et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost 2009; 7: 746-51.
17. Gandhi R, Razak F, Tso P, Davey JR, Mahomed NN. Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty. J Rheumatol 2009; 36: 2298-301.
18. Vaya A, Martinez-Triguero ML, Espana F, Todoli JA, Bonet E, Corella D. The metabolic syndrome and its individual components: its association with venous thromboembolism in a Mediterranean population. Metab Syndr Relat Disord 2011; 9: 197-201.
19. He W, Gao P, Chu L, Yin L, Li Z, Xie Y. Electrochemical synthesis of porous cobalt nanowall arrays. Nanotechnology 2006; 17: 3512-17.
20. Eliasson A, Bergqvist D, Bjorck M, Acosta S, Sternby NH, Ogren M. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23, 796 consecutive autopsies. J Thromb Haemost 2006; 4: 1897-902.
21. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223-33.
22. Reich LM, Folsom AR, Key NS, et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006; 4: 1909-13.
23. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-60.
24. Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc. 2006; 81: 59-68.
25. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.
26. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis 2010; 20: 140-6.
27. Esposito K, Ciotola M, Carleo D, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29: 1071-6.
28. Dell'Omo G, Penno G, Pucci L, Mariani M, Del Prato S, Pedrinelli R. Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. Atherosclerosis 2004; 172: 383-9.
29. Hamburg NM, Larson MG, Vita JA, et al. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham Offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol 2008; 101: 82-8.
30. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 2005; 112: 32-8.
31. Bahia L, Aguiar LG, Villela N, et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 2007; 195: 138-46.
32. Barton M. Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr Hypertens Rep 2000; 2: 84-91.
33. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
34. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14-22.
35. Lind L. Endothelium-dependent vasodilation, insulin resistance and the metabolic syndrome in an elderly cohort: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 2008; 196: 795-802.
36. Kullo IJ, Malik AR. Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification. J Am Coll Cardiol 2007; 49: 1413-26.
37. Ghiadoni L, Taddei S, Virdis A. Hypertension and Endothelial Dysfunction: Therapeutic Approach. Curr Vasc Pharmacol 2011; in press.
38. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO 3rd. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995; 91: 1732-8.
39. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endotheliumdependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-74.
40. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109: 613-9.
41. Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep 2010; 12: 448-55.
42. Kizhakekuttu TJ, Widlansky ME. Natural antioxidants and hypertension: promise and challenges. Cardiovasc Ther 2010; 28: e20-32.
43. Widder JD, Fraccarollo D, Galuppo P, et al. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension 2009; 54: 338-44.
44. Vecchione C, Carnevale D, Di Pardo A, et al. Pressure-induced vascular oxidative stress is mediated through activation of integrinlinked kinase 1/betaPIX/Rac-1 pathway. Hypertension 2009; 54: 1028-34.
45. Juonala M, Viikari JS, Ronnemaa T, Helenius H, Taittonen L, Raitakari OT. Elevated blood pressure in adolescent boys predicts endothelial dysfunction: the cardiovascular risk in young Finns study. Hypertension 2006; 48: 424-30.
46. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 1999; 33: 937-42.
47. Shimbo D, Muntner P, Mann D, et al. Endothelial dysfunction and the risk of hypertension: the multi-ethnic study of atherosclerosis. Hypertension 2010; 55: 1210-6.
48. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-6.
49. Festa A, D'Agostino R, Jr., Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562-8.
50. Vehkavaara S, Seppala-Lindroos A, Westerbacka J, Groop PH, Yki-Jarvinen H. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 1999; 22: 2055-60.
51. Rodriguez CJ, Miyake Y, Grahame-Clarke C, et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol 2005; 96: 1273-7.
52. Henry RM, Ferreira I, Kostense PJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis 2004; 174: 49-56.
53. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000; 36: 2185-91.
54. Weil BR, Stauffer BL, Mestek ML, Desouza CA. Influence of abdominal obesity on vascular endothelial function in overweight/obese adult men. Obesity (Silver Spring) 2011; 19: 1742-6.
55. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50: 159-65.
56. Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001; 88: 1264-9.
57. Arcaro G, Zamboni M, Rossi L, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 1999; 23: 936-42.
58. Kuvin JT, Patel AR, Sidhu M, et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol 2003; 92: 275-9.
59. Lupattelli G, Marchesi S, Roscini AR, et al. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. Am J Cardiol 2002; 90: 648-50.
60. Lupattelli G, Lombardini R, Schillaci G, et al. Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles. Am Heart J 2000; 140: 521-6.
61. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-6.
62. Rasmussen JG, Eschen RB, Aardestrup IV, Dethlefsen C, Griffin BA, Schmidt EB. Flow-mediated vasodilatation: variation and interrelationships with plasma lipids and lipoproteins. Scand J Clin Lab Invest 2009; 69: 156-60.
63. Schnell GB, Robertson A, Houston D, Malley L, Anderson TJ. Impaired brachial artery endothelial function is not predicted by elevated triglycerides. J Am Coll Cardiol 1999; 33: 2038-43.
64. Chowienczyk PJ, Watts GF, Wierzbicki AS, Cockcroft JR, Brett SE, Ritter JM. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J Am Coll Cardiol 1997; 29: 964-8.
65. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-2.
66. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
67. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-301.
68. Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ J 2007; 71: 1120-7.
69. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466-71.
70. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39-42.
71. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59: 1276-82.
72. Kuwahata S, Hamasaki S, Ishida S, et al. Effect of uric acid on coronary microvascular endothelial function in women: association with eGFR and ADMA. J Atheroscler Thromb 2010; 17: 259-69.
73. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-4.
74. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
75. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
76. Sheng CS, Hu BC, Fan WX, Zou J, Li Y, Wang JG. Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. Diabetol Metab Syndr 2011; 3: 6.
77. Janssen SF, Twickler TB, Jublanc C, Cramer MJ, Bruckert E. Patients with the metabolic syndrome and a disturbed cortisol balance display more microalbuminuria. Diab Vasc Dis Res 2008; 5: 54-8.
78. Leoncini G, Ratto E, Viazzi F, et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 2005; 257: 454-60.
79. Yuyun MF, Khaw KT, Luben R, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004; 159: 284-93.
80. Solbu MD, Jenssen TG, Eriksen BO, Toft I. Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension-the impact of microalbuminuria: a 13-year followup study. Metabolism 2009; 58: 408-15.
81. Perticone F, Maio R, Tripepi G, Sciacqua A, Mallamaci F, Zoccali C. Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J Nephrol 2007; 20: S56-62.
82. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study. Kidney Int Suppl 2004: S42-4.
83. Pedrinelli R, Dell'Omo G, Penno G, Mariani M. Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med 2001; 6: 257-64.
84. Asselbergs FW, de Boer RA, Diercks GF, et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004; 93: 211-5.
85. Ayerden Ebinc F, Haksun E, Ulver DB, et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med 2008; 47: 1511-6.
86. Kario K, Matsuo T, Kobayashi H, et al. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996; 16: 455-61.
87. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698-705.
88. Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 2010; 23: 1183-9.
89. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011; 56: 3439-49.
90. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
91. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
92. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
93. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
94. Devaraj S, Jialal I. Dysfunctional endothelial progenitor cells in metabolic syndrome. Exp Diabetes Res 2012; 2012: 585018.
95. Katsiki N, Athyros VG, Mikhailidis DP. Does metabolic syndrome influence outcome following percutaneous coronary intervention? Angiology 2011; 62: 437-9.
96. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009; 20: 295-302.
97. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-904.
98. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-9.
99. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-20.
100. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104: 447-57.
101. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-49.
102. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007; 101: 27-39.
103. Muscogiuri G, Chavez AO, Gastaldelli A, et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 2008; 6: 301-12.
104. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-7.
105. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010; 170: 1622-31.
106. Marti-Carvajal AJ, Sola I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009 (4): CD006612.
107. Mok CC, Poon WL, Lai JP, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol 2010; 39: 42-9.
108. Green A, Dobias SB, Walters DJ, Brasier AR. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 1994; 134: 2581-8.
109. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003; 170: 21-9.
110. Kashyap SR, Belfort R, Cersosimo E, Lee S, Cusi K. Chronic lowdose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects. J Cardiometab Syndr 2008; 3: 141-6.
111. Sarafidis PA, Bakris GL. Review: Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007; 92: 379-85.
112. Donatelli M, Hoffmann E, Colletti I, et al. Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol 1996; 33: 246-8.
113. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-62.
114. Piatti PM, Monti LD, Galli L, et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000; 49: 748-52.
115. Piatti P, Fragasso G, Monti LD, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol 1999; 34: 1452-60.
116. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98: 2453-60.
117. Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib Nephrol 2006; 151: 122-34.
118. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010; 100: 525-34.
119. Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C. Cardiovascular and metabolic effects of ghrelin. Curr Diabetes Rev 2010; 6: 228-35.
120. Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and desoctanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res 2006; 69: 227-35.
121. Iantorno M, Chen H, Kim JA, et al. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 2007; 292: E756-64.
122. Tesauro M, Schinzari F, Iantorno M, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112: 2986-92.
123. Tesauro M, Schinzari F, Rovella V, et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009; 54: 995-1000.
124. Beaumont NJ, Skinner VO, Tan TM, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003; 278: 8877-80.
125. Moncada S, Higgs EA. Prostaglandins in the pathogenesis and prevention of vascular disease. Blood Rev 1987; 1: 141-5.
126. Das UN. A defect in Delta6 and Delta5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians. Lipids Health Dis 2010; 9: 130.
127. Sato N, Kaneko M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 2010; 59: 1092-100.
128. Peredo HA, Mayer MA, Carranza A, Puyo AM. Pioglitazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fructose-overloaded rats. Clin Exp Hypertens 2008; 30: 159-69.
129. Puyo AM, Mayer MA, Giorgi S, Gomez AH, Peredo HA. Noradrenaline and angiotensin II modify vascular prostanoid release in fructose-fed hypertensive rats. Auton Autacoid Pharmacol 2007; 27: 161-5.
130. Puyo AM, Zabalza M, Mayer M, Carranza A, Peredo HA. Time course of vascular prostanoid production in the fructosehypertensive rat. Auton Autacoid Pharmacol 2009; 29: 135-9.
131. Title LM, Lonn E, Charbonneau F, et al. Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome. Vasc Med 2008; 13: 263-70.
132. You T, Nicklas BJ, Ding J, et al. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci 2008; 63: 414-9.
133. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-6.
134. Schindler TH, Nitzsche EU, Olschewski M, et al. Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. Circulation 2004; 110: 1069-75.
135. Nakamura T, Takano H, Umetani K, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181: 321-7.
136. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007; 153: 881-8.
137. Ingelsson E, Hulthe J, Lind L. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest 2008; 38: 502-9.
138. Indulekha K, Surendar J, Mohan V. High sensitivity C-reactive protein, tumor necrosis factor-alpha, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). J Diabetes Sci Technol 2011; 5: 982-8.
139. Muscara MN, Vergnolle N, Lovren F, et al. Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000; 129: 1423-30.
140. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelialdependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 2005; 28: 702-7.
141. Perticone F, Maio R, Sciacqua A, et al. Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 2008; 57: 167-71.
142. Phillips SA, Jurva JW, Syed AQ, et al. Benefit of low-fat over lowcarbohydrate diet on endothelial health in obesity. Hypertension 2008; 51: 376-82.
143. Katcher HI, Legro RS, Kunselman AR, et al. The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. Am J Clin Nutr 2008; 87: 79-90.
144. Volek JS, Ballard KD, Silvestre R, et al. Effects of dietary carbohydrate restriction versus low-fat diet on flow-mediated dilation. Metabolism 2009; 58: 1769-77.
145. Galisteo M, Sanchez M, Vera R, et al. A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-alpha in obese Zucker rats. J Nutr 2005; 135: 2399-404.
146. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterraneanstyle diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440-6.
147. Angelico F, Loffredo L, Pignatelli P, et al. Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Intern Emerg Med 2011; in press.
148. Lopez-Miranda J, Perez-Jimenez F, Ros E, et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. Nutr Metab Cardiovasc Dis 2010; 20: 284-94.
149. Perez-Martinez P, Garcia-Rios A, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Mediterranean diet rich in olive oil and obesity, metabolic syndrome and diabetes mellitus. Curr Pharm Des 2011; 17: 769-77.
150. Perez-Martinez P, Moreno-Conde M, Cruz-Teno C, et al. Dietary fat differentially influences regulatory endothelial function during the postprandial state in patients with metabolic syndrome: from the LIPGENE study. Atherosclerosis 2010; 209: 533-8.
151. Al-Solaiman Y, Jesri A, Mountford WK, Lackland DT, Zhao Y, Egan BM. DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre. J Hum Hypertens 2010; 24: 237-46.
152. Poudyal H, Panchal S, Brown L. Comparison of purple carrot juice and beta-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. Br J Nutr 2010; 104: 1322-32.
153. Wennersberg MH, Smedman A, Turpeinen AM, et al. Dairy products and metabolic effects in overweight men and women: results from a 6-mo intervention study. Am J Clin Nutr 2009; 90: 960-8.
154. van Meijl LE, Mensink RP. Effects of low-fat dairy consumption on markers of low-grade systemic inflammation and endothelial function in overweight and obese subjects: an intervention study. Br J Nutr 2010; 104: 1523-7.
155. de Mello VD, Schwab U, Kolehmainen M, et al. A diet high in fatty fish, bilberries and wholegrain products improves markers of endothelial function and inflammation in individuals with impaired glucose metabolism in a randomised controlled trial: the Sysdimet study. Diabetologia 2011; 54: 2755-67.
156. Vazquez-Prieto MA, Renna NF, Lembo C, Diez ER, Miatello RM. Dealcoholized red wine reverse vascular remodeling in an experimental model of metabolic syndrome: role of NAD(P)H oxidase and eNOS activity. Food Funct 2010; 1: 124-9.
157. Aronis KN, Vamvini MT, Chamberland JP, et al. Short-term walnut consumption increases circulating total adiponectin and apolipoprotein A concentrations, but does not affect markers of inflammation or vascular injury in obese humans with the metabolic syndrome: data from a double-blinded, randomized, placebo-controlled study. Metabolism 2011; in press.
158. Lopez-Uriarte P, Nogues R, Saez G, et al. Effect of nut consumption on oxidative stress and the endothelial function in metabolic syndrome. Clin Nutr 2010; 29: 373-80.
159. Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Hu FB, Willett WC. Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. Diabetes Care 2007; 30: 967-73.
160. Seligman BG, Polanczyk CA, Santos AS, et al. Intensive practical lifestyle intervention improves endothelial function in metabolic syndrome independent of weight loss: a randomized controlled trial. Metabolism 2011; 60: 1736-40.
161. Roberts CK, Won D, Pruthi S, et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2006; 100: 1657-65.
162. Setola E, Monti LD, Galluccio E, et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 2004; 151: 483-9.
163. Brook RD, Bard RL, Glazewski L, et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 2004; 93: 1012-6.
164. Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 2005: 409-15.
165. Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 2006; 32: 372-80.
166. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol 2010; 105: 1284-8.
167. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-7.
168. Ly HQ, Kirtane AJ, Murphy SA, et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol 2006; 98: 1-5.
169. Paul GK, Sen B, Bari MA, et al. Correlation of platelet count and acute ST-elevation in myocardial infarction. Mymensingh Med J 2010; 19: 469-73.
170. Molnar MZ, Streja E, Kovesdy CP, et al. High platelet count as a link between renal cachexia and cardiovascular mortality in endstage renal disease patients. Am J Clin Nutr 2011; 94: 945-54.
171. Panwar RB, Gupta R, Gupta BK, et al. Atherothrombotic risk factors & premature coronary heart disease in India: a case-control study. Indian J Med Res 2011; 134: 26-32.
172. Sadreddini SA, Abolfathi AA, Khandagi R, Talebi M, Lakian A. Creactive protein, fibrinogen, lipoprotein (a), and lipid profile levels and platelet counts in ischemic stroke patients. Neurosciences (Riyadh) 2007; 12: 202-6.
173. van der Bom JG, Heckbert SR, Lumley T, et al. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost 2009; 7: 399-405.
174. Kotani K, Sakane N, Saiga K, Mu H, Kurozawa Y. Clustered components of the metabolic syndrome and platelet counts in Japanese females. Clin Chem Lab Med 2007; 45: 376-9.
175. Jesri A, Okonofua EC, Egan BM. Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2005; 7: 705-11.
176. Jayachandran M, Litwiller RD, Lahr BD, et al. Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res 2011; 4: 811-22.
177. Lohsoonthorn V, Jiamjarasrungsi W, Williams MA. Association of Hematological Parameters with Clustered Components of Metabolic Syndrome among Professional and Office Workers in Bangkok, Thailand. Diabetes Metab Syndr 2007; 1: 143-9.
178. Park BJ, Shim JY, Lee HR, Jung DH, Lee JH, Lee YJ. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. Platelets 2012; 23: 45-50.
179. Samocha-Bonet D, Justo D, Rogowski O, et al. Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm 2008; 2008: 834153.
180. Charles LE, Fekedulegn D, McCall T, Burchfiel CM, Andrew ME, Violanti JM. Obesity, white blood cell counts, and platelet counts among police officers. Obesity (Silver Spring) 2007; 15: 2846-54.
181. Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007; 293: E656-65.
182. Taniguchi A, Fukushima M, Seino Y, et al. Platelet count is independently associated with insulin resistance in non-obese Japanese type 2 diabetic patients. Metabolism 2003; 52: 1246-9.
183. Asdie RH, Sa'adah, Jazakillah S, Sinorita H. Does insulin resistance correlate with routine blood examination? A review on erythrocytes of obese patients. Acta Med Indones 2009; 41: 66-9.
184. Chen LK, Lin MH, Chen ZJ, Hwang SJ, Chiou ST. Association of insulin resistance and hematologic parameters: study of a middleaged and elderly Chinese population in Taiwan. J Chin Med Assoc 2006; 69: 248-53.
185. Zapolski T, Wacinski P, Kondracki B, Rychta E, Buraczynska MJ, Wysokinski A. Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiol Pol 2011; 69: 319-26.
186. Sigola LB, Adewuyi JO, Mufunda J. Plasma fibrinogen levels, leucocyte and platelet counts in male Zimbabwean hypertensives. Cent Afr J Med 1992; 38: 447-50.
187. Coban E, Yazicioglu G, Berkant Avci A, Akcit F. The mean platelet volume in patients with essential and white coat hypertension. Platelets 2005; 16: 435-8.
188. Harries AD, Beeching NJ, Rogerson SJ, Nye FJ. The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea. J Infect 1991; 22: 247-50.
189. Santimone I, Di Castelnuovo A, De Curtis A, et al. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. Haematologica 2011; 96: 1180-8.
190. Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Interrelationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost 2007; 5: 1637-43.
191. Kirilmaz B, Asgun F, Alioglu E, et al. High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens (Greenwich) 2010; 12: 136-44.
192. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.
193. Jagroop IA, Kakafika AI, Mikhailidis DP. Platelets and vascular risk: an option for treatment. Curr Pharm Des 2007; 13: 1669-83.
194. Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003; 25: 16-22.
195. Papathanasiou AI, Goudevenos JA, Mikhailidis DP, Tselepis AD. Acute and long-term antiplatelet therapy. Drugs Today (Barc) 2008; 44(5): 331-352.
196. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003; 9: 177-90.
197. Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med 2011; 12: 312-22.
198. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009; 63: 1509-15.
199. Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404.
200. Tekbas E, Kara AF, Ariturk Z, et al. Mean platelet volume in predicting short-and long-term morbidity and mortality in patients with or without ST-segment elevation myocardial infarction. Scand J Clin Lab Invest 2011; 71: 613-9.
201. Demirtunc R, Duman D, Basar M. Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. Clin Drug Investig 2007; 27: 435-41.
202. Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007; 120: 245-50.
203. Yazici HU, Poyraz F, Sen N, et al. Relationship between mean platelet volume and left ventricular systolic function in patients with metabolic syndrome and ST-elevation myocardial infarction. Clin Invest Med 2011; 34: E330.
204. Vaduganathan M, Alviar CL, Arikan ME, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J 2008; 156: 1002 e1001-1002 e1007.
205. Restituto P, Colina I, Varo JJ, Varo N. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 298: E1072-77.
206. Vaidya D, Yanek LR, Faraday N, Moy TF, Becker LC, Becker DM. Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. Metab Syndr Relat Disord 2009; 7: 289-96.
207. Serebruany VL, Malinin A, Ong S, Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis 2008; 25: 207-13.
208. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of plateletmonocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-ST elevation acute coronary syndromes. Clin Cardiol 2007; 30: 26-31.
209. Arteaga RB, Chirinos JA, Soriano AO, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006; 98: 70-4.
210. Ludwig RJ, Schon MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets 2007; 11: 1103-17.
211. Cleanthis M, Smout J, Bhattacharya V, et al. Soluble but not platelet P-selectin correlates with spontaneous platelet aggregation: a pilot study. Clin Appl Thromb Hemost 2008; 14: 227-33.
212. Genc H, Dogru T, Tapan S, et al. Soluble CD40 ligand, soluble Pselectin and von Willebrand factor levels in subjects with prediabetes: The impact of metabolic syndrome. Clin Biochem 2012; 45: 92-5.
213. Kleiman NS. GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology. Drugs R D 1999; 1: 361-70.
214. Anderluh M, Dolenc MS. Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. Curr Med Chem 2002; 9: 1229-50.
215. Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD. Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 2005; 16: 368-71.
216. van der Zee PM, Biro E, Ko Y, et al. P-selectin-and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006; 52: 657-64.
217. Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 2010; 26: 140-5.
218. Helal O, Defoort C, Robert S, et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis 2011; 21: 665-71.
219. Ueba T, Haze T, Sugiyama M, et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 2008; 100: 280-5.
220. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
221. Natal C, Restituto P, Inigo C, Colina I, Diez J, Varo N. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab 2008; 93: 2319-27.
222. Unek IT, Bayraktar F, Solmaz D, et al. Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism 2010; 59: 305-13.
223. Vaidya D, Szklo M, Cushman M, et al. Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: multi-ethnic study of atherosclerosis. Eur J Clin Nutr 2011; 65: 818-25.
224. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004; 16: 169-74.
225. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-5.
226. Santilli F, Vazzana N, Liani R, Guagnano MT, Davi G. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012; 13: 27-42.
227. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005; 59: 981-2.
228. Coban E, Yilmaz A, Sari R. The effect of weight loss on the mean platelet volume in obese patients. Platelets 2007; 18: 212-6.
229. De Pergola G, Pannacciulli N, Coviello M, et al. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors. Nutr Metab Cardiovasc Dis 2008; 18: 227-32.
230. Csongradi E, Nagy B Jr., Fulop T, et al. Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. Thromb Haemost 2011; 106: 683-92.
231. Basili S, Pacini G, Guagnano MT, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-8.
232. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-14.
233. Russo I, Traversa M, Bonomo K, et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity (Silver Spring) 2010; 18: 788-97.
234. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988; 157: 1190-6.
235. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1988; 37: 780-6.
236. Touyz RM, Schiffrin EL. Blunted inhibition by insulin of agoniststimulated calcium, pH and aggregatory responses in platelets from hypertensive patients. J Hypertens 1994; 12: 1255-63.
237. Trovati M, Anfossi G, Massucco P, et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate. Diabetes 1997; 46: 742-9.
238. Novgorodtseva TP, Karaman YK, Zhukova NV, Lobanova EG, Antonyuk MV, Kantur TA. Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. Lipids Health Dis 2011; 10: 82.
239. Ueba T, Nomura S, Inami N, et al. Correlation and association of plasma interleukin-6 and plasma platelet-derived microparticles, markers of activated platelets, in healthy individuals. Thromb Res 2010; 125: e329-34.
240. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-71.
241. Pignatelli P, De Biase L, Lenti L, et al. Tumor necrosis factoralpha as trigger of platelet activation in patients with heart failure. Blood 2005; 106: 1992-4.
242. Aukrust P, Halvorsen B, Ueland T, et al. Activated platelets and atherosclerosis. Expert Rev Cardiovasc Ther 2010; 8: 1297-307.
243. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-7.
244. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
245. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12: 180-6.
246. Victor VM, Rocha M, Sola E, Banuls C, Garcia-Malpartida K, Hernandez-Mijares A. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009; 15: 2988-3002.
247. Pignatelli P, Sanguigni V, Lenti L, et al. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004; 110: 1326-9.
248. Begonja AJ, Gambaryan S, Geiger J, et al. Platelet NAD(P)Hoxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood 2005; 106: 2757-60.
249. Colas R, Sassolas A, Guichardant M, et al. LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia 2011; 54: 2931-40.
250. Patrono C, Falco A, Davi G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 2005; 5: 198-203.
251. Anfossi G, Russo I, Trovati M. Platelet resistance to the antiaggregating agents in the insulin resistant states. Curr Diabetes Rev 2006; 2: 409-30.
252. Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3230-5.
253. Guagnano MT, Ferroni P, Santilli F, et al. Determinants of platelet activation in hypertensives with microalbuminuria. Free Radic Biol Med 2009; 46: 922-7.
254. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-isoprostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
255. Varo N, Libby P, Nuzzo R, Italiano J, Doria A, Schonbeck U. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2005; 2: 81-7.
256. Gannage-Yared MH, Khalife S, Semaan M, Fares F, Jambart S, Halaby G. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol 2006; 155: 167-76.
257. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007; 558: 7-13.
258. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptindependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.
259. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287: 1706-9.
260. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-9.
261. Esteghamati A, Noshad S, Khalilzadeh O, et al. Contribution of serum leptin to metabolic syndrome in obese and nonobese subjects. Arch Med Res 2011; 42: 244-51.
262. Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006; 26: 224-30.
263. Mikhailidis DP, Barradas MA, Maris A, Jeremy JY, Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol 1985; 38: 1166-71.
264. Peredo HA, Mayer MA, Rodriguez Fermepin M, Grinspon D, Puyo AM. Oral treatment and in vitro incubation with fructose modify vascular prostanoid production in the rat. Auton Autacoid Pharmacol 2006; 26: 15-20.
265. Jagroop IA, Mikhailidis DP. Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl. Platelets 2000; 11: 272-7.
266. Jagroop IA, Daskalopoulou SS, Mikhailidis DP. Endothelin-1 and human platelets. Curr Vasc Pharmacol 2005; 3: 393-9.
267. Mohan IV, Jagroop IA, Mikhailidis DP, Stansby GP. Homocysteine activates platelets in vitro. Clin Appl Thromb Hemost 2008; 14: 8-18.
268. Murakami T, Horigome H, Tanaka K, et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res 2007; 119: 45-53.
269. Barradas MA, Christofides JA, Jeremy JY, Mikhailidis DP, Fry DE, Dandona P. The effect of olive oil supplementation on human platelet function, serum cholesterol-related variables and plasma fibrinogenconcentrations: A pilot study. Nutr Res 1990; 10: 403-11.
270. Sikora J, Broncel M, Markowicz M, Chalubinski M, Wojdan K, Mikiciuk-Olasik E. Short-term supplementation with Aronia melanocarpa extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome. Eur J Nutr 2011; in press.
271. Barre DE. The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes-a mini-review. J Oleo Sci 2007; 56: 319-25.
272. Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-9.
273. Suehiro A, Wakabayashi I, Uchida K, Yamashita T, Yamamoto J. Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome. Thromb Res 2011; in press.
274. Lip GY, Blann AD. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J Hypertens 1998; 16: 1557-9.
275. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6: 1327-33.
276. Orbe J, Zudaire M, Serrano R, et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008; 99: 382-7.
277. Kassel KM, Owens AP 3rd, Rockwell CE, et al. Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. Am J Pathol 2011; 179: 2278-89.
278. Angelico F, Alessandri C, Ferro D, et al. Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia 2006; 49: 1169-74.
279. Kopp CW, Kopp HP, Steiner S, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003; 11: 950-6.
280. Kotronen A, Joutsi-Korhonen L, Sevastianova K, et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int 2011; 31: 176-83.
281. Kain K, Carter AM, Grant PJ, Scott EM. Alanine aminotransferase is associated with atherothrombotic risk factors in a British South Asian population. J Thromb Haemost 2008; 6: 737-41.
282. Meerarani P, Moreno PR, Cimmino G, Badimon JJ. Atherothrombosis: role of tissue factor; link between diabetes, obesity and inflammation. Indian J Exp Biol 2007; 45: 103-10.
283. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105: S43-54.
284. Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci (Elite Ed) 2012; 4: 289-99.
285. Nakagomi A, Sasaki M, Ishikawa Y, et al. Upregulation of monocyte tissue factor activity is significantly associated with carotid intima-media thickness in patients with metabolic syndrome. J Atheroscler Thromb 2011; 18: 475-86.
286. Nakagomi A, Sasaki M, Ishikawa Y, et al. Upregulation of monocyte tissue factor activity is significantly associated with lowgrade chronic inflammation and insulin resistance in patients with metabolic syndrome. Circ J 2010; 74: 572-7.
287. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-7.
288. Fang WQ, Zhang Q, Peng YB, et al. Resistin level is positively correlated with thrombotic complications in Southern Chinese metabolic syndrome patients. J Endocrinol Invest 2011; 34: e36-42.
289. Noto D, Cefalu AB, Barbagallo CM, et al. Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study. Acta Diabetol 2011; in press.
290. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care 2010; 33: 2266-70.
291. Marckmann P. Dietary treatment of thrombogenic disorders related to the metabolic syndrome. Br J Nutr 2000; 83: S121-6.
292. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older nondiabetic men. Atherosclerosis 2005; 181: 101-8.
293. Freeman MS, Mansfield MW, Barrett JH, Grant PJ. Insulin resistance: an atherothrombotic syndrome. The Leeds family study. Thromb Haemost 2003; 89: 161-8.
294. Mieszczanska H, Kaba NK, Francis CW, et al. Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. J Thromb Haemost 2007; 5: 942-9.
295. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-9.
296. Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population-II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost 1985; 54: 721-3.
297. Godsland IF, Crook D, Proudler AJ, Stevenson JC. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 190-7.
298. Pieters M, Oosthuizen W, Jerling JC, Loots DT, Mukuddem-Petersen J, Hanekom SM. Clustering of haemostatic variables and the effect of high cashew and walnut diets on these variables in metabolic syndrome patients. Blood Coagul Fibrinolysis 2005; 16: 429-37.
299. Dai K, Bodnar R, Berndt MC, Du X. A critical role for 14-3-3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications. Blood 2005; 106: 1975-81.
300. Razdan K, Hellums JD, Kroll MH. Shear-stress-induced von Willebrand factor binding to platelets causes the activation of tyrosine kinase(s). Biochem J. 1994; 302: 681-6.
301. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672-7.
302. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
303. Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 2010; 41: 2151-6.
304. Ragab A, Abousamra NK, Higazy A, Saleh O. Relationship between insulin resistance and some coagulation and fibrinolytic parameters in patients with metabolic syndrome. Lab Hematol 2008; 14: 1-6.
305. Lim HS, Lip GY, Blann AD. Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab 2004; 89: 5377-81.
306. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308-14.
307. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
308. Mertens I, Van Gaal LF. Visceral fat as a determinant of fibrinolysis and hemostasis. Semin Vasc Med 2005; 5: 48-55.
309. Sjogren P, Basta G, de Caterina R, et al. Markers of endothelial activity are related to components of the metabolic syndrome, but not to circulating concentrations of the advanced glycation endproduct N epsilon-carboxymethyl-lysine in healthy Swedish men. Atherosclerosis 2007; 195: e168-75.
310. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374-80.
311. de Saint Martin L, Pasquier E, Vandhuick O, et al. Correlations between carotid IMT, factor VIII activity level and metabolic disturbances: a cardio-vascular risk factor in the HIV positive persons. Curr HIV Res 2007; 5: 361-4.
312. Woodward M, Lowe GD, Rumley A, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97: 785-97.
313. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults-the ARIC study. Atherosclerosis Risk in Communities. Obes Res 2000; 8: 279-86.
314. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
315. Antonini-Canterin F, La Carrubba S, Gullace G, et al. Association between carotid atherosclerosis and metabolic syndrome: results from the ISMIR study. Angiology 2010; 61: 443-8.
316. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204-10.
317. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
318. Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007; 13: 1647-59.
319. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemost 2005; 11: 139-46.
320. Palomo IG, Gutierrez CL, Alarcon ML, et al. Increased concentration of plasminogen activator inhibitor-1 and fibrinogen in individuals with metabolic syndrome. Mol Med Report 2009; 2: 253-7.
321. Vaya A, Carmona P, Badia N, Perez R, Hernandez Mijares A, Corella D. Homocysteine levels and the metabolic syndrome in a Mediterranean population: a case-control study. Clin Hemorheol Microcirc 2011; 47: 59-66.
322. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 1998; 21: 649-54.
323. Vaya A, Hernandez-Mijares A, Bonet E, et al. Association between hemorheological alterations and metabolic syndrome. Clin Hemorheol Microcirc 2011; 49: 493-503.
324. Simao AN, Lozovoy MA, Simao TN, et al. Immunological and biochemical parameters of patients with metabolic syndrome and the participation of oxidative and nitroactive stress. Braz J Med Biol Res 2011; 44: 707-12.
325. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351-8.
326. Kressel G, Trunz B, Bub A, et al. Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis 2009; 202: 263-71.
327. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
328. Ramkumar N, Murtaugh MA, Cheung AK, Beddhu S. Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. Am J Kidney Dis 2007; 49: 356-64.
329. Ma J, Xu A, Jia C, et al. Associations of fibrinogen with metabolic syndrome in rural Chinese population. J Atheroscler Thromb 2010; 17: 486-92.
330. Basoglu OK, Sarac F, Sarac S, Uluer H, Yilmaz C. Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome. Ann Thorac Med 2011; 6: 120-5.
331. Church TS, Finley CE, Earnest CP, Kampert JB, Gibbons LW, Blair SN. Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome. Int J Obes Relat Metab Disord 2002; 26: 805-13.
332. Valek J, Valkova L, Vlasakova Z, Topinka V. Increased fibrinogen levels in the offspring of hypertensive men. Relation with hyperinsulinemia and the metabolic syndrome. Arterioscler Thromb Vasc Biol 1995; 15: 2229-33.
333. Dietzen DJ, Jack GG, Page KL, Tetzloff TA, Hall CL, Mast AE. Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity. Thromb Haemost 2003; 89: 65-73.
334. Onat A, Ozhan H, Erbilen E, et al. Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels. Int J Cardiol 2009; 135: 211-7.
335. Rogowski O, Shapira I, Bassat OK, et al. Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional study. J Inflamm (Lond) 2010; 7: 35.
336. Rudnicka AR, Rumley A, Whincup PH, Lowe GD, Strachan DP. Sex differences in the relationship between inflammatory and hemostatic biomarkers and metabolic syndrome: British 1958 Birth Cohort. J Thromb Haemost 2011; 9: 2337-44.
337. Chrusciel P, Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH. Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. Med Sci Monit 2009; 15: RA203-8.
338. Sola E, Vaya A, Simo M, et al. Fibrinogen, plasma viscosity and blood viscosity in obesity. Relationship with insulin resistance. Clin Hemorheol Microcirc 2007; 37: 309-18.
339. Sola E, Jover A, Lopez-Ruiz A, et al. Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss. Obes Surg 2009; 19: 571-6.
340. Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 1996; 16: 381-5.
341. Luyckx FH, Scheen AJ, Desaive C, Dewe W, Gielen JE, Lefebvre PJ. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes Metab 1998; 24: 355-61.
342. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52: 329-33.
343. Aloulou I, Varlet-Marie E, Mercier J, Brun JF. Hemorheologic effects of low intensity endurance training in sedentary patients suffering from the metabolic syndrome. Clin Hemorheol Microcirc 2006; 35: 333-9.
344. Dumortier M, Brandou F, Perez-Martin A, Fedou C, Mercier J, Brun JF. Low intensity endurance exercise targeted for lipid oxidation improves body composition and insulin sensitivity in patients with the metabolic syndrome. Diabetes Metab 2003; 29: 509-18.
345. Greie S, Humpeler E, Gunga HC, et al. Improvement of metabolic syndrome markers through altitude specific hiking vacations. J Endocrinol Invest 2006; 29: 497-504.
346. Sialvera TE, Pounis GD, Koutelidakis AE, et al. Phytosterols supplementation decreases plasma small and dense LDL levels in metabolic syndrome patients on a westernized type diet. Nutr Metab Cardiovasc Dis 2011; in press.
347. Wolfram RM, Kritz H, Efthimiou Y, Stomatopoulos J, Sinzinger H. Effect of prickly pear (Opuntia robusta) on glucose-and lipidmetabolism in non-diabetics with hyperlipidemia-a pilot study. Wien Klin Wochenschr 2002; 114: 840-6.
348. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
349. Sabovic M, Lavre S, Keber I. Supplementation of wheat fibre can improve risk profile in patients with dysmetabolic cardiovascular syndrome. Eur J Cardiovasc Prev Rehabil 2004; 11: 144-8.
350. Bye A, Tjonna AE, Stolen TO, Rosbjorgen RE, Wisloff U. Transcriptional changes in blood after aerobic interval training in patients with the metabolic syndrome. Eur J Cardiovasc Prev Rehabil 2009; 16: 47-52.
351. Hamdy O, Ledbury S, Mullooly C, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 2119-25.
352. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-7.
353. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31: 26-32.
354. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-5.
355. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
356. Koster A, Stenholm S, Alley DE, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) 2010; 18: 2354-61.
357. Al-Hamodi Z, Ismail IS, Saif-Ali R, Ahmed KA, Muniandy S. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol 2011; 10: 23.
358. Boronat M, Saavedra P, Varillas VF, et al. Differences in traditional and emerging cardiovascular risk factors of subjects discordantly classified by metabolic syndrome definitions of the International Diabetes Federation and the National Cholesterol Education Program. Nutr Metab Cardiovasc Dis 2009; 19: 417-22.
359. Coffey CS, Asselbergs FW, Hebert PR, et al. The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels. Cardiol Res Pract 2011; 2011: 541467.
360. Wildman RP, Kaplan R, Manson JE, et al. Body size phenotypes and inflammation in the Women's Health Initiative Observational Study. Obesity (Silver Spring) 2011; 19: 1482-91.
361. Chou YY, Sheu WH, Tang YJ, et al. Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan. Arch Gerontol Geriatr 2009; 49: S41-5.
362. Boronat M, Saavedra P, Varillas VF, Novoa FJ. Use of confirmatory factor analysis for the identification of new components of the metabolic syndrome: the role of plasminogen activator inhibitor-1 and Haemoglobin A1c. Nutr Metab Cardiovasc Dis 2009; 19: 271-6.
363. Ajjan R, Carter AM, Somani R, Kain K, Grant PJ. Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome. J Thromb Haemost 2007; 5: 754-60.
364. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753-9.
365. Alessi MC, Nicaud V, Scroyen I, et al. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D. E. S. I. R. prospective cohort. Thromb Haemost 2011; 106: 416-22.
366. Festa A, D'Agostino R, Jr., Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
367. Galli-Tsinopoulou A, Grammatikopoulou MG, Stylianou C, Emmanouilidou E, Kokka P. Diabese youngsters have 3. 7 more chances in developing metabolic syndrome compared with the obese. J Endocrinol Invest 2010; 33: 549-53.
368. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.
369. Kraja AT, Province MA, Arnett D, et al. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab (Lond) 2007; 4: 28.
370. Aso Y, Wakabayashi S, Yamamoto R, et al. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005; 28: 2211-6.
371. de Larranaga G, Wingeyer SP, Graffigna M, et al. Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. Clin Appl Thromb Hemost 2008; 14: 319-24.
372. Rosito GA, D'Agostino RB, Massaro J, et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91: 683-9.
373. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-8.
374. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-64.
375. Schalkwijk CG, Stehouwer CD. PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy. Thromb Haemost 2006; 96: 698-9.
376. Bouchard L, Vohl MC, Lebel S, et al. Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity. Obes Surg 2010; 20: 492-9.
377. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-70.
378. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994; 89: 321-30.
379. Miyagawa R, Asakura T, Nakamura T, et al. Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3'-untranslated region of the PAI-1 gene and its pharmacologic implications. Coron Artery Dis 2010; 21: 144-50.
380. Soardo G, Donnini D, Domenis L, et al. Oxidative stress is activated by free fatty acids in cultured human hepatocytes. Metab Syndr Relat Disord 2011; 9: 397-401.
381. Sakamoto K, Sakamoto T, Ogawa H. Effects of metabolic risk factors on production of plasminogen activator inhibitor-1 and adiponectin by adipocytes. Circ J 2008; 72: 844-6.
382. Okazaki M, Iwasaki Y, Jing H, et al. Insulin enhancement of cytokine-induced coagulation/inflammation-related gene transcription in hepatocytes. Endocr J 2008; 55: 967-75.
383. Sakamoto T, Woodcock-Mitchell J, Marutsuka K, Mitchell JJ, Sobel BE, Fujii S. TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am J Physiol 1999; 276: C1391-7.
384. Lumeng CN. Adipose tissue macrophages: a piece of the PAI of metabolic syndrome. Sci Transl Med 2010; 2: 20ps27.
385. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-10.
386. Jaulmes A, Sansilvestri-Morel P, Rolland-Valognes G, et al. Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells. Thromb Res 2009; 124: 439-46.
387. Zhao R, Ma X, Shen GX. Transcriptional regulation of plasminogen activator inhibitor-1 in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell Biochem 2008; 317: 197-204.
388. Kuniyasu A, Tokunaga M, Yamamoto T, et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes. Biochim Biophys Acta 2011; 1811: 153-62.
389. Iwasaki H, Okamoto R, Kato S, et al. High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rhokinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 2008; 196: 22-8.
390. Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008; 100: 969-75.
391. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodriguez-Iturbe B, Natarajan R. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int 2005; 68: 2787-93.
392. Viallard JF, Blanco P, Andre M, et al. CD8+HLA-DR+ T lymphocytes are increased in common variable immunodeficiency patients with impaired memory B-cell differentiation. Clin Immunol 2006; 119: 51-8.
393. Li P, Zhang XN, Pan CM, et al. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res 2011; 43: 464-9.
394. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-11.
395. van der Bom JG, de Knijff P, Haverkate F, et al. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997; 95: 2623-7.
396. Alizadeh Dehnavi R, Beishuizen ED, van de Ree MA, et al. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. Eur J Intern Med 2008; 19: 115-21.
397. Kimura K, Iguchi Y, Shibazaki K, et al. Early stroke treatment with IV t-PA associated with early recanalization. J Neurol Sci 2010; 295: 53-7.
398. Arenillas JF, Ispierto L, Millan M, et al. Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke. Neurology 2008; 71: 190-5.
399. Arenillas JF, Sandoval P, Perez de la Ossa N, et al. The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men. Stroke 2009; 40: 344-9.
400. Christensen JO, Svendsen OL, Hassager C, Christiansen C. Leptin in overweight postmenopausal women: no relationship with metabolic syndrome X or effect of exercise in addition to diet. Int J Obes Relat Metab Disord 1998; 22: 195-9.
401. Morris PJ, Packianathan CI, Van Blerk CJ, Finer N. Moderate exercise and fibrinolytic potential in obese sedentary men with metabolic syndrome. Obes Res 2003; 11: 1333-8.
402. Ades PA, Savage PD, Toth MJ, et al. High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. Circulation 2009; 119: 2671-8.
403. Alzamendi A, Giovambattista A, Raschia A, et al. Fructose-rich diet-induced abdominal adipose tissue endocrine dysfunction in normal male rats. Endocrine 2009; 35: 227-32.
404. Vrolix R, Mensink RP. Effects of glycemic load on metabolic risk markers in subjects at increased risk of developing metabolic syndrome. Am J Clin Nutr 2010; 92: 366-74.
405. Byberg L, Smedman A, Vessby B, Lithell H. Plasminogen activator inhibitor-1 and relations to fatty acid composition in the diet and in serum cholesterol esters. Arterioscler Thromb Vasc Biol 2001; 21: 2086-92.
406. Montegaard C, Tulk HM, Lauritzen L, Tholstrup T, Robinson LE. Acute ingestion of long-chain (n-3) polyunsaturated fatty acids decreases fibrinolysis in men with metabolic syndrome. J Nutr 2010; 140: 38-43.
407. Landin K, Holm G, Tengborn L, Smith U. Guar gum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin Nutr 1992; 56: 1061-5.
408. Windberger U, Bartholovitsch A, Plasenzotti R, Korak KJ, Heinze G. Whole blood viscosity, plasma viscosity and erythrocyte aggregation in nine mammalian species: reference values and comparison of data. Exp Physiol 2003; 88: 431-40.
409. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997; 96: 168-73.
410. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992; 117: 371-5.
411. Dormandy JA, Edelman JB. High blood viscosity: an aetiological factor in venous thrombosis. Br J Surg 1973; 60: 187-90.
412. Irace C, Scavelli F, Carallo C, Serra R, Gnasso A. Plasma and blood viscosity in metabolic syndrome. Nutr Metab Cardiovasc Dis 2009; 19: 476-80.
413. Brunner EJ, Hemingway H, Walker BR, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002; 106: 2659-65.
414. Caimi G, Sinagra D, Scarpitta AM, Lo Presti R. Plasma viscosity and insulin resistance in metabolic syndrome. Int J Obes Relat Metab Disord 2001; 25: 1856-7.
415. Carroll S, Cooke CB, Butterly RJ. Plasma viscosity, fibrinogen and the metabolic syndrome: effect of obesity and cardiorespiratory fitness. Blood Coagul Fibrinolysis 2000; 11: 71-8.
416. Zhang L, Pu K, Zhang SY, Ren WQ. Blood rheological properties are strongly related to the metabolic syndrome in middle-aged Chinese. Int J Cardiol 2006; 112: 229-33.
417. Kostapanos MS, Elisaf M, Mikhailidis DP. Obstructive sleep apnea and cardiovascular risk: is metabolic syndrome the link? Angiology 2012; 63: 569-73.
418. Liak C, Fitzpatrick M. Coagulability in obstructive sleep apnea. Can Respir J 2011; 18: 338-48.
419. Brun JF, Aloulou I, Varlet-Marie E. Hemorheological aspects of the metabolic syndrome: markers of insulin resistance, obesity or hyperinsulinemia? Clin Hemorheol Microcirc 2004; 30: 203-9.
420. Aloulou I, Varlet-Marie E, Mercier J, Brun JF. The hemorheological aspects of the metabolic syndrome are a combination of separate effects of insulin resistance, hyperinsulinemia and adiposity. Clin Hemorheol Microcirc 2006; 35: 113-9.
421. Brun JF, Varlet-Marie E, de Mauverger ER, Mercier J. Minimal model-derived insulin sensitivity, insulin secretion and glucose tolerance: relationships with blood rheology. Clin Hemorheol Microcirc 2012; 51: 21-7.
422. Brun JF, Varlet-Marie E, Fedou C, Raynaud de Mauverger E. Body composition and exercise performance as determinants of blood rheology in middle-aged patients exhibiting the metabolic syndrome. Clin Hemorheol Microcirc 2011; 49: 215-23.
423. Vaya A, Hernandez-Mijares A, Suescun M, et al. Metabolic alterations in morbid obesity. Influence on the haemorheological profile. Clin Hemorheol Microcirc 2011; 48: 247-55.
424. Aloulou I, Varlet-Marie E, Mercier J, Brun JF. Hemorheological disturbances correlate with the lipid profile but not with the NCEPATPIII score of the metabolic syndrome. Clin Hemorheol Microcirc 2006; 35: 207-12.
425. Hoieggen A, Fossum E, Moan A, Enger E, Kjeldsen SE. Wholeblood viscosity and the insulin-resistance syndrome. J Hypertens 1998; 16: 203-10.
426. Tamariz LJ, Young JH, Pankow JS, et al. Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 2008; 168: 1153-60.
427. Brun JF, Varlet-Marie E, Cassan D, Raynaud de Mauverger E. Blood rheology and body composition as determinants of exercise performance in female rugby players. Clin Hemorheol Microcirc 2011; 49: 207-14.